How profitable is ENDRA Life Sciences Inc. (NDRA)?

In FY 2025 (10-K), NDRA converted $16.1M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / NDRA / financials

IRIX (27) ITOC (33) NUWE (33) NXL (32) ⌘ Pro Terminal →

ENDRA Life Sciences Inc. (NDRA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.80 +1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.80

ENDRA Life Sciences Inc. (NDRA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $7.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NDRA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.80 (+1.05% 1D, market cap $7.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NDRA ranks #581 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NDRA compare to IRIX and ITOC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $19.0M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NDRA?

▼

Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $16.1M in revenue (-46.7% YoY), -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.80 (+0.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NDRA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY NDRA SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 42.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.04-11.3% Next Q

Q2 (-2Q)

Grade D$4.47+11% Next Q

Q3 (-1Q)

Grade E$4.96-3.2% Next Q

Current

Grade D-$4.80-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NDRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NDRA currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.45) and Max Pain ($5.04) forces dealer call-delta covering toward $7.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NDRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NDRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NDRA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $29.5M

FY24

Rev $30.3M

FY25

Rev $16.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$16.1M	52%	-35.7%	-$7.0M	-$5.2M	-45%
FY 2024	$30.3M	52%	-35.7%	-$11.5M	-$7.4M	-45%
FY 2023	$29.5M	52%	-35.7%	-$10.1M	-$9.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NDRA)

✓Walkthrough of NDRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NDRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.83%📐 HORIZONTAL RANGE

2026-11-03O $4.88H $4.88L $4.75C $4.80VOL 10.6K

RES: $6.82SUP: $4.30SMA50: $5.45SMA200: $4.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NDRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NDRA Butterfly Map → + Track NDRA →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -46.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NDRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NDRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NDRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NDRA)

Health Care Rank #581 of 1015 ⚔️ IRIX vs NDRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NDRA vs. IRIX, ITOC, NUWE, NXL)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ENDRA Life Sciences Inc. (NDRA) ranks #581 by composite RQD confidence (36/100, grade D-) and #918 by equity capitalization ($7.1M). Within this direct 5-issuer industry benchmark cohort, NDRA leads on earnings valuation at N/A trailing P/E, while NDRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently leads its immediate peer cohort in composite quantitative strength at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NDRA ACTIVE ENDRA Life Sciences Inc.	D-	36/100	—	—	-35.0%	+1.05%	$7.1M	Benchmark Subject
IRIX IRIDEX Corporation	E	27/100	—	36.5%	-35.0%	+1.33%	$12.5M	/irix-vs-ndra →
ITOC iTonic Holdings Ltd (Class A)	E	33/100	—	62.6%	-35.0%	-9.61%	$19.0M	/itoc-vs-ndra →
NUWE Nuwellis Inc.	E	33/100	—	62.0%	-35.0%	-8.80%	$2.3M	/nuwe-vs-ndra →
NXL Nexalin Technology Inc.	E	32/100	—	79.7%	-35.0%	-5.94%	$1.8M	/nxl-vs-ndra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681682 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported GAAP revenue of $16.1M (-46.7% vs. FY2024 revenue of $30.3M , and -45.2% cumulative change since FY2023) , GAAP net income of -$7.0M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+29.9% YoY). On the balance sheet, NDRA closed FY2025 with $3.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.1M	-$7.0M	-$5.2M	-$5.2M	$3.9M	—
FY2024 (FY)	2024-12-31	$30.3M	-$11.5M	-$7.4M	-$7.4M	$4.5M	—
FY2023 (FY)	2023-12-31	$29.5M	-$10.1M	-$9.5M	-$9.5M	—	—

3. NDRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NDRA compare to IRIX and ITOC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NDRA?

Where is NDRA trading relative to its 50-day, 200-day, and 52-week technical levels?

NDRA last traded at $4.80 (+1.05% on volume of 5,797 shares), positioning the stock -11.93% below its 50-day simple moving average ($5.45) and -0.21% below its 200-day simple moving average ($4.81). Across its 52-week range of $2.96 to $6.95, NDRA sits at the 46.1% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.20 to $5.40).

Direct Sub-Reports: NDRA RQD Cockpit NDRA 12M Forecast NDRA Earnings & Move NDRA Dividends & DRIP NDRA Insiders & 13F NDRA Whale Options NDRA Profit Sankey NDRA News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

NDRA — ENDRA Life Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ENDRA Life Sciences Inc. (NDRA) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.80 (+1.05% 1D, market capitalization $7.1M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ENDRA Life Sciences Inc. (NDRA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. It carries a market capitalization of $0.0B, which is inconsistent with the $7.3M figure in market data and should be treated with caution. — describes its specific products, customers, or revenue model. Reported revenue is — in each listed period.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported $16.1M in annual revenue (up from $30.3M in FY2024, -46.7% YoY) and -$7.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($29.5M revenue, -$10.1M net income) through FY2025, NDRA scaled operating cash flow to -$5.2M and free cash flow to -$5.2M, backed by $3.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.96 – $6.95 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that the absence of mapped links means this dossier cannot identify which suppliers, customers, or sector peers would transmit shocks to NDRA.

Key Question #1: Can NDRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$5.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NDRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NDRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ENDRA Life Sciences Inc. (NDRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NDRA Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

ENDRA Life Sciences Inc. Estimates – NASDAQ:NDRA

TradingView report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Daré Bioscience, Inc. (DARE) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Daré Bioscience, Inc. (DARE) stock price, news, quote and history

Yahoo Finance UK report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingKey • 1d ago

Top U.S. Stock Gainers: Biggest Price Increases

TradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago

ProPhase Labs, Inc. (PRPH) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 2d ago

52-Week Low U.S. Stocks & New Market Lows

TradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 2d ago

bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history

Yahoo Finance Australia report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 2d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering ENDRA Life Sciences Inc. (NDRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NDRA Bull vs. Bear Conversation Board — What's Your Call at $4.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NDRA 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $5.89 (+24.0%)

📌 Pinned Debate

The stock trades at $4.88 with a 52-week range of $2.96 - $6.95 and a 2.95% daily gain, with a GREEN-flagged catalyst item in the news

Here is why I am bullish on NDRA here at $4.75: The stock trades at $4.88 with a 52-week range of $2.96 - $6.95 and a 2.95% daily gain, with a GREEN-flagged catalyst item in the news feed.. Compare NDRA's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Electromedical & Electrotherapeutic Apparatus. As long as cash conversion holds up, dips toward $4.51 are getting bought.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 5/20 institutional whale-flow stock at $4.75 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $3.75 (-21.1%)

Spot @ $4.75

The company reports zero revenue, negative FCF in every period, ROIC of -35%, and cash falling from $3.2M to $0.8M, with an RQD score o

The company reports zero revenue, negative FCF in every period, ROIC of -35%, and cash falling from $3.2M to $0.8M, with an RQD score of 42.. Look at the math on NDRA: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $4.18 before getting long.